Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
Stryker Corporation (NYSE:SYK ) Wells Fargo 2024 Healthcare Conference Call September 5, 2024 3:00 PM ET Company Participants Spencer Stiles - Group President, Orthopedics and Spine Jason Beach - Vice President, Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo All right, welcome back. I'm Larry Biegelsen, the medical device analyst at Wells Fargo.
Stryker (SYK) reported earnings 30 days ago. What's next for the stock?
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.
Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.